Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. filed this Form 8-K on September 20, 2018, to report the completion of a private placement transaction. The Company, incorporated in Nevada, entered into a Securities Purchase Agreement with three institutional investors to raise capital through the sale of Convertible Notes and Common Stock Purchase Warrants.
Key Financial Metrics and Transaction Details
- Total Proceeds: $169,676.00
- Principal Amount of Notes: $183,250.08 per investor (Total principal obligation exceeds cash proceeds due to accrued interest or discount structure).
- Interest Rate: 8% per annum.
- Maturity Date: September 20, 2019.
- Warrant Coverage: 1,247,618 shares of common stock per investor.
- Warrant Exercise Price: $0.088 per share.
- Warrant Term: Five years.
Material Changes and Terms
The filing details the creation of a direct financial obligation and the unregistered sale of equity securities. Key terms include:
- Conversion Feature: Notes are convertible into common stock beginning 31 days after closing. The conversion price is set at 65% of the "Market Price," defined as the lowest trading price during the 20 trading days preceding the conversion date.
- Anti-Dilution Protection: Warrants include a full ratchet anti-dilution adjustment for future issuances of common stock, subject to exceptions.
- Regulatory Basis: The transaction was conducted under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b).
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding future operations. However, the transaction introduces specific financial risks:
- Dilution Risk: The 65% conversion discount and full ratchet anti-dilution provisions on warrants create significant potential for future equity dilution.
- Liquidity Obligation: The Company has a fixed debt obligation maturing in one year, contingent on conversion or repayment.
- Market Price Volatility: The conversion price is tied to the lowest trading price over a 20-day period, which may incentivize conversion during periods of low stock valuation.
Investor Verification Checklist
- Verify the Company's current cash position to assess its ability to service the 8% interest or repay the principal if conversion does not occur.
- Review the "Market Price" definition impact on potential dilution given the 65% conversion discount.
- Examine the specific exceptions to the full ratchet anti-dilution provision in the attached Warrant agreement (Exhibit 4.2).
- Confirm the identity of the three institutional investors and any related party relationships.
- Check subsequent filings for any amendments to the Notes or Warrants or early conversions.